3 completed, 3 terminated. 4 Phase 2, 2 Phase 1.
By phase and status
Follow VIP-ELP fusion molecule PB1046: new trials by email Literature Review of VIP-ELP fusion molecule PB1046 trials Research Report on VIP-ELP fusion molecule PB1046
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
Pemziviptadil (PB1046) Injection - Pulmonary Arterial Hypertension | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 25 | 2019-04-10 | 2022-02-22 |
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
Pemziviptadil (PB1046) - Pulmonary Arterial Hypertension | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 35 | 2018-07-15 | 2022-08-23 |
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF
PB1046 Injection, Placebo Injection - Heart Failure | Phase 2 | Completed | PhaseBio Pharmaceuticals Inc. | 29 | 2016-06-01 | 2022-07-14 |
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
Placebo Single IV (Intravenous) Infusion, Experimental: Single IV Infusion Vasomera (PB1046) - Essential Hypertension | Phase 1 | Completed | PhaseBio Pharmaceuticals Inc. | 20 | 2013-06-01 | 2014-04-10 |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
Vasomera (PB1046), 0.9% Sodium Chloride - Essential Hypertension | Phase 1 | Completed | PhaseBio Pharmaceuticals Inc. | 68 | 2012-01-01 | 2013-01-04 |
Conditions studied
Essential Hypertension (2) · Heart Failure (2) · Pulmonary Arterial Hypertension (2) · COVID-19 (1) · Cardiovascular Diseases (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Dyspnea (1) · Hypertension (1) · Myocardial Infarction (1) · Pneumonia (1) · Pulmonary Edema (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
Sponsors
PhaseBio Pharmaceuticals Inc. (6)
Countries
United States (6)
Top investigators
Mark Matson, MD (1) · William B. Smith, MD (1)